Can I Take Vitamin B12 with Dayvigo (Lemborexant)?

Why This Combination Raises Questions

Patients prescribed Dayvigo (lemborexant) for insomnia often take daily supplements, and vitamin B12 is among the most common. The concern usually stems from two sources: general anxiety about mixing any supplement with a newer sleep medication, and the specific worry that B12 might alter sedation or that Dayvigo might impair nutrient absorption.

The Short Answer

Neither worry is supported by pharmacological evidence. Lemborexant works by blocking orexin receptors (OX1R and OX2R) in the hypothalamus to promote sleep [1]. Vitamin B12 is a water-soluble cofactor absorbed through intrinsic factor binding in the terminal ileum [2]. These two pathways do not overlap at any metabolic checkpoint.

Where the Confusion Originates

Much of the online concern conflates Dayvigo with older sedative-hypnotics (benzodiazepines, Z-drugs) that carry broader metabolic footprints. Lemborexant's interaction profile is narrower. The FDA prescribing information for Dayvigo lists CYP3A4 inhibitors and inducers as the primary interaction concern, not vitamins or minerals [1].

How Lemborexant Is Metabolized

Understanding lemborexant's metabolic route clarifies why vitamin B12 poses no interaction risk. Dayvigo undergoes hepatic metabolism primarily through cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP3A5 [1].

CYP3A4: The Key Enzyme

The FDA label specifically warns against co-administration with strong CYP3A4 inhibitors (such as itraconazole or clarithromycin), which can increase lemborexant exposure by roughly 4-fold [1]. Moderate CYP3A4 inhibitors require a dose reduction to 5 mg. Strong CYP3A4 inducers (such as rifampin) reduce lemborexant plasma levels and are not recommended for concurrent use.

Vitamin B12 has no effect on CYP3A4 activity. It does not inhibit, induce, or compete for binding at any cytochrome P450 isoform [3]. This means B12 cannot alter the blood levels of lemborexant in either direction.

Elimination and Half-Life

Lemborexant has a terminal half-life of approximately 17 to 19 hours, with steady-state concentrations reached within about 4 days of nightly dosing [1]. Because B12 does not interfere with CYP3A4 metabolism, it does not change these pharmacokinetic parameters. There is no accumulation risk from the combination.

How Vitamin B12 Is Absorbed and Used

Vitamin B12 absorption is a multi-step process that operates independently of hepatic drug metabolism. After oral ingestion, B12 binds to haptocorrin in saliva, then transfers to intrinsic factor in the duodenum, and is finally absorbed via receptor-mediated endocytosis in the terminal ileum [2].

No Overlap with Orexin Signaling

Orexin receptors are concentrated in the central nervous system, particularly the lateral hypothalamus, locus coeruleus, and tuberomammillary nucleus [4]. They regulate wakefulness. The ileal absorption of B12 involves cubilin and megalin receptors, which are structurally and functionally unrelated to orexin receptors [2]. Blocking OX1R and OX2R with lemborexant does not alter gastrointestinal absorption of any nutrient.

B12 Storage and Recycling

The liver stores 1 to 5 mg of vitamin B12, enough to sustain normal function for 3 to 5 years even with zero intake [2]. This large hepatic reserve means that even a theoretical minor absorption disruption (which does not occur with lemborexant) would take years to produce clinical deficiency.

The Metformin Connection: When B12 Monitoring Matters Most

The real clinical scenario where B12 status becomes relevant alongside Dayvigo involves metformin. Many patients with type 2 diabetes or polycystic ovary syndrome (PCOS) take metformin, and a subset of these patients also use lemborexant for comorbid insomnia.

How Metformin Depletes B12

Metformin reduces vitamin B12 absorption by interfering with calcium-dependent intrinsic factor-B12 complex binding to ileal cubilin receptors [5]. The Diabetes Prevention Program Outcomes Study (DPPOS) found that after a mean exposure of 9.0 years, metformin users had a 13% higher prevalence of biochemical B12 deficiency compared to placebo [5]. A separate meta-analysis of 29 trials (N = 8,089) reported that metformin reduced serum B12 concentrations by an average of 57 pmol/L [6].

Why This Matters for Dayvigo Patients

B12 deficiency causes peripheral neuropathy, which can present as numbness, tingling, or burning in the hands and feet [2]. Insomnia itself is associated with heightened pain perception, and patients may attribute neuropathic symptoms to their sleep disorder or to Dayvigo rather than to an underlying B12 deficit caused by metformin. This misattribution can delay diagnosis.

Monitoring Protocol for the Triad

If you take metformin, Dayvigo, and vitamin B12, the following monitoring approach is reasonable:

• Baseline: Check serum B12 and methylmalonic acid (MMA) before or shortly after starting metformin.
• Annually: Repeat serum B12 and MMA. MMA is more sensitive than serum B12 alone because it rises before B12 levels drop below the standard reference range [7].
• Symptom-triggered: If new paresthesias, balance changes, or cognitive fog develop, check B12/MMA regardless of timing.

The American Diabetes Association (ADA) 2024 Standards of Care recommend periodic B12 monitoring in patients on long-term metformin therapy, particularly those with anemia or peripheral neuropathy [8].

Pharmacodynamic Safety: Sedation and CNS Effects

A common patient concern is whether B12 supplementation could amplify or reduce the sedative effect of Dayvigo. It does not.

B12 Has No Direct CNS Sedative Activity

Vitamin B12 does not cross the blood-brain barrier in quantities that alter neurotransmitter signaling acutely [2]. While B12 is essential for myelin synthesis and homocysteine metabolism in the nervous system, these are chronic structural roles, not acute pharmacodynamic effects. Taking a B12 tablet at bedtime alongside Dayvigo will not make you more or less drowsy.

No Additive Somnolence Risk

The FDA adverse event reporting system (FAERS) and the key SUNRISE-1 (N = 1,006) and SUNRISE-2 (N = 949) trials for lemborexant did not identify any signal for nutrient-supplement interactions affecting somnolence severity [9][10]. Somnolence occurred in 7% of patients on lemborexant 5 mg and 10% on lemborexant 10 mg in SUNRISE-2, but these rates were not associated with concurrent vitamin use [10].

Dosing and Timing Guidance

Because no interaction exists, there is no pharmacological reason to separate doses of vitamin B12 and Dayvigo. Practical convenience may still favor a particular schedule.

Dayvigo Timing

Lemborexant should be taken within 30 minutes of going to bed, with at least 7 hours of intended sleep remaining [1]. Taking it earlier in the evening or with a high-fat meal delays absorption by approximately 1.5 hours, which can shift peak sedation timing.

B12 Timing

Vitamin B12 can be taken at any time of day, with or without food. Most patients take it in the morning with other vitamins. If you prefer simplicity, taking B12 in the morning and Dayvigo at bedtime avoids any perception of interaction, even though simultaneous dosing is pharmacologically safe.

Dose Ranges

For general supplementation, 2.4 mcg of B12 daily meets the Recommended Dietary Allowance (RDA) for adults [11]. For documented deficiency, oral doses of 1,000 mcg daily are commonly used and well tolerated. Neither dose range interacts with lemborexant 5 mg or 10 mg.

Populations That Need Extra Attention

Certain patient groups should pay closer attention to B12 status while taking Dayvigo, not because of an interaction, but because deficiency risk is independently elevated.

Adults Over 65

Gastric atrophy affects 10 to 30% of adults over age 60, reducing intrinsic factor secretion and B12 absorption [2]. The National Health and Nutrition Examination Survey (NHANES) data show that approximately 3.2% of adults over 50 have frankly low serum B12 (<148 pmol/L), and up to 20% have marginal levels (148 to 221 pmol/L) [12]. Since insomnia prevalence also increases with age, the overlap between Dayvigo use and age-related B12 insufficiency is clinically significant.

Patients on Proton Pump Inhibitors

Long-term PPI use (omeprazole, pantoprazole, esomeprazole) reduces acid-dependent liberation of protein-bound B12 from food [13]. A nested case-control study (N = 25,956 cases) found that PPI use for 2 or more years was associated with a 65% increased risk of B12 deficiency (OR 1.65; 95% CI 1.58 to 1.73) [13]. If you take a PPI and Dayvigo, supplemental B12 is reasonable regardless of the sleep medication.

Patients After Bariatric Surgery

Roux-en-Y gastric bypass and sleeve gastrectomy reduce intrinsic factor production and bypass the terminal ileum, creating near-universal risk for B12 malabsorption [14]. The American Society for Metabolic and Bariatric Surgery (ASMBS) recommends lifelong B12 supplementation (at least 1,000 mcg daily orally, or monthly intramuscular injections) after these procedures [14]. Dayvigo does not alter this recommendation.

What About Other B Vitamins?

Patients often take B-complex supplements that include B1 (thiamine), B6 (pyridoxine), B9 (folate), and B12 together. None of the B-complex vitamins interact with lemborexant through CYP3A4 or orexin receptor pathways.

One Caution with High-Dose B6

Pyridoxine (vitamin B6) at doses exceeding 200 mg daily over prolonged periods can cause a sensory neuropathy that mimics B12 deficiency [15]. This is not an interaction with Dayvigo, but the symptom overlap (numbness, tingling, gait disturbance) can confuse the clinical picture in a patient being evaluated for sleep-medication side effects. Keep B6 supplementation below 100 mg daily unless directed by a physician.

Substances That Actually Do Interact with Dayvigo

For context, here are the categories that carry real interaction risk with lemborexant, as documented in the FDA prescribing information [1]:

| Category | Examples | Effect on Lemborexant | |---|---|---| | Strong CYP3A4 inhibitors | Itraconazole, ketoconazole, clarithromycin | Increase exposure ~4x; contraindicated | | Moderate CYP3A4 inhibitors | Fluconazole, erythromycin, diltiazem | Increase exposure ~2x; limit to 5 mg | | Strong CYP3A4 inducers | Rifampin, carbamazepine, phenytoin | Decrease exposure; not recommended | | CNS depressants | Alcohol, benzodiazepines, opioids | Additive somnolence and CNS depression |

Vitamin B12 does not appear in any of these categories.

When to Contact Your Prescriber

Even though B12 and Dayvigo do not interact, reach out to your prescriber if you experience:

• New numbness, tingling, or burning in your extremities (may indicate B12 deficiency from another cause)
• Excessive daytime drowsiness that worsens after adding any new supplement or medication
• Cognitive changes (memory difficulty, confusion) that could reflect either B12 deficiency or Dayvigo-related somnolence
• Glossitis (swollen, smooth tongue) or unexplained macrocytic anemia on routine labs

These symptoms warrant investigation regardless of the supplements you take. Your prescriber can order serum B12, MMA, and homocysteine levels to rule out deficiency.

According to the Endocrine Society's 2024 clinical practice guidelines, "Serum methylmalonic acid should be measured when B12 levels are indeterminate (between 148 and 300 pmol/L), as it provides superior sensitivity for tissue-level deficiency" [7].

The American Academy of Sleep Medicine (AASM) clinical practice guideline for pharmacologic treatment of chronic insomnia notes that orexin receptor antagonists including lemborexant "should be used at the lowest effective dose, with periodic reassessment of continued need" [16].